Cargando…

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

AIMS: The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. MATERIALS AND METHODS: A total of 7637 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, Richard E., Emerson, Scott S., Franek, Edward, Gilbert, Matthew P., Marso, Steven P., McGuire, Darren K., Pieber, Thomas R., Zinman, Bernard, Hansen, Charlotte T., Hansen, Melissa V., Mark, Thomas, Moses, Alan C., Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617815/
https://www.ncbi.nlm.nih.gov/pubmed/30850995
http://dx.doi.org/10.1111/dom.13699
_version_ 1783433777005985792
author Pratley, Richard E.
Emerson, Scott S.
Franek, Edward
Gilbert, Matthew P.
Marso, Steven P.
McGuire, Darren K.
Pieber, Thomas R.
Zinman, Bernard
Hansen, Charlotte T.
Hansen, Melissa V.
Mark, Thomas
Moses, Alan C.
Buse, John B.
author_facet Pratley, Richard E.
Emerson, Scott S.
Franek, Edward
Gilbert, Matthew P.
Marso, Steven P.
McGuire, Darren K.
Pieber, Thomas R.
Zinman, Bernard
Hansen, Charlotte T.
Hansen, Melissa V.
Mark, Thomas
Moses, Alan C.
Buse, John B.
author_sort Pratley, Richard E.
collection PubMed
description AIMS: The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. MATERIALS AND METHODS: A total of 7637 patients in the DEVOTE trial, a treat‐to‐target, randomized, double‐blind trial evaluating the CV safety of degludec vs glargine U100, were divided into three age groups (50‐64 years, n = 3682; 65‐74 years, n = 3136; ≥75 years, n = 819). Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all‐cause mortality, severe hypoglycaemia and serious adverse events (SAEs). RESULTS: Patients with increasing age had higher risks of CV death, all‐cause mortality and SAEs, and there were non‐significant trends towards higher risks of MACE and severe hypoglycaemia. Treatment effects on the risk of MACE, all‐cause mortality, severe hypoglycaemia and SAEs were consistent across age groups, based on the non‐significant interactions between treatment and age with regard to these outcomes. CONCLUSIONS: There were higher risks of CV death, all‐cause mortality and SAEs, and trends towards higher risks of MACE and severe hypoglycaemia with increasing age after adjusting for baseline differences. The effects across age groups of degludec vs glargine U100 on MACE, all‐cause mortality and severe hypoglycaemia were comparable, suggesting that the risk of MACE, as well as all‐cause mortality, is similar and the risk of severe hypoglycaemia is lower with degludec regardless of age. Evidence is conclusive only until 74 years of age.
format Online
Article
Text
id pubmed-6617815
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-66178152019-07-22 Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) Pratley, Richard E. Emerson, Scott S. Franek, Edward Gilbert, Matthew P. Marso, Steven P. McGuire, Darren K. Pieber, Thomas R. Zinman, Bernard Hansen, Charlotte T. Hansen, Melissa V. Mark, Thomas Moses, Alan C. Buse, John B. Diabetes Obes Metab Original Articles AIMS: The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. MATERIALS AND METHODS: A total of 7637 patients in the DEVOTE trial, a treat‐to‐target, randomized, double‐blind trial evaluating the CV safety of degludec vs glargine U100, were divided into three age groups (50‐64 years, n = 3682; 65‐74 years, n = 3136; ≥75 years, n = 819). Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all‐cause mortality, severe hypoglycaemia and serious adverse events (SAEs). RESULTS: Patients with increasing age had higher risks of CV death, all‐cause mortality and SAEs, and there were non‐significant trends towards higher risks of MACE and severe hypoglycaemia. Treatment effects on the risk of MACE, all‐cause mortality, severe hypoglycaemia and SAEs were consistent across age groups, based on the non‐significant interactions between treatment and age with regard to these outcomes. CONCLUSIONS: There were higher risks of CV death, all‐cause mortality and SAEs, and trends towards higher risks of MACE and severe hypoglycaemia with increasing age after adjusting for baseline differences. The effects across age groups of degludec vs glargine U100 on MACE, all‐cause mortality and severe hypoglycaemia were comparable, suggesting that the risk of MACE, as well as all‐cause mortality, is similar and the risk of severe hypoglycaemia is lower with degludec regardless of age. Evidence is conclusive only until 74 years of age. Blackwell Publishing Ltd 2019-04-15 2019-07 /pmc/articles/PMC6617815/ /pubmed/30850995 http://dx.doi.org/10.1111/dom.13699 Text en © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Pratley, Richard E.
Emerson, Scott S.
Franek, Edward
Gilbert, Matthew P.
Marso, Steven P.
McGuire, Darren K.
Pieber, Thomas R.
Zinman, Bernard
Hansen, Charlotte T.
Hansen, Melissa V.
Mark, Thomas
Moses, Alan C.
Buse, John B.
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
title Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
title_full Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
title_fullStr Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
title_full_unstemmed Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
title_short Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
title_sort cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine u100 in patients with type 2 diabetes aged 65 years or older: results from devote (devote 7)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617815/
https://www.ncbi.nlm.nih.gov/pubmed/30850995
http://dx.doi.org/10.1111/dom.13699
work_keys_str_mv AT pratleyricharde cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT emersonscotts cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT franekedward cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT gilbertmatthewp cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT marsostevenp cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT mcguiredarrenk cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT pieberthomasr cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT zinmanbernard cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT hansencharlottet cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT hansenmelissav cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT markthomas cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT mosesalanc cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT busejohnb cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7
AT cardiovascularsafetyandlowerseverehypoglycaemiaofinsulindegludecversusinsulinglargineu100inpatientswithtype2diabetesaged65yearsorolderresultsfromdevotedevote7